PharmaCyte Biotech Reports Director/Officer Changes & Shareholder Votes

TL;DR

PharmaCyte Biotech filed an 8-K detailing director/officer changes and shareholder votes.

AI Summary

PharmaCyte Biotech, Inc. filed an 8-K on October 31, 2025, reporting on events as of October 30, 2025. The filing covers the departure and election of directors, appointment of officers, and compensatory arrangements. It also includes information on matters submitted to a vote of security holders and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant corporate governance changes and potential shareholder engagement on key company matters, which could impact the company's strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with shareholder votes, can signal internal shifts or strategic decisions that may carry inherent business risks.

Key Players & Entities

• PharmaCyte Biotech, Inc. (company) — Registrant
• October 30, 2025 (date) — Earliest event reported
• October 31, 2025 (date) — Date of report
• Nevada (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock , Par Value $0.0001 Per Share PMCB The Nasdaq Stock Ma

Filing Documents

• pharmacyte_8k.htm (8-K) — 36KB
• pharmacyte_ex1001.htm (EX-10.1) — 116KB
• 0001683168-25-007871.txt ( ) — 343KB
• pmcb-20251030.xsd (EX-101.SCH) — 3KB
• pmcb-20251030_lab.xml (EX-101.LAB) — 33KB
• pmcb-20251030_pre.xml (EX-101.PRE) — 22KB
• pharmacyte_8k_htm.xml (XML) — 4KB

02 Departure of Directors or

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) At the Special Meeting (as defined below), stockholders of PharmaCyte Biotech, Inc. (the "Company") approved an amendment to the Company's 2022 Equity Incentive Plan to, among other things, increase the number of shares of the Company's common stock (the "Common Stock") available for the grant of awards by 2,250,000 shares (as amended, the "2022 Equity Incentive Plan"). The foregoing description of the 2022 Equity Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the 2022 Equity Incentive Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

07 Submission of Matters to a Vote of

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 30, 2025, the Company held a special meeting of stockholders (the "Special Meeting") via live webcast. At the Special Meeting, 2,866,944 shares of voting stock, or approximately 37.1% of the outstanding shares of stock entitled to vote at the meeting, were represented by proxy or in person, representing a quorum. At the Special Meeting, the stockholders of the Company voted as set forth below on three proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on October 6, 2025. The final voting results for each matter submitted to a vote of the Company's stockholders are as follows: Proposal 1. Issuance of Shares of our Common Stock. The Company's stockholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of (a) that certain Securities Purchase Agreement, dated August 17, 2025, by and among the Company and the investors named therein and (b) that certain engagement letter by and among the Company and GP Nurmenkari Inc. as placement agent, in an amount equal to or in excess of 20% of the Company's Common Stock outstanding before the issuance of such convertible preferred stock and warrants (including upon the operation ofanti-dilution provisions contained in such convertible preferred stock and warrants), by the following votes: Shares Voted For Shares Voted Against Abstentions 1,649,395 249,100 47,316 Proposal 2. Amendment to the Company's 2022 Equity Incentive Plan. The Company's stockholders voted to approve a proposed amendment to the Company's 2022 Equity Incentive Plan to, among other things, increase the number of shares available for the grant of awards by 2,250,000 shares, by the following votes: Shares Vo

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed as part of this report: Exhibit Number Description 10.1 PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan, As Amended 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHARMACYTE BIOTECH, INC. Date: October 31, 2025 By: /s/ Joshua N. Silverman Name: Joshua N. Silverman Title: Chief Executive Officer and President 4

View Full Filing

View this 8-K filing on SEC EDGAR